Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 4Prostatic Neoplasms 3Neoplasm Metastasis 3Ovarian Neoplasms 2Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Brain Neoplasms 2Adenocarcinoma of Lung 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Recurrence, Local 1

Interventions

Carboplatin 24Pemetrexed 18Cisplatin 17Paclitaxel 14pembrolizumab 13Gemcitabine 8osimertinib 7durvalumab 6Docetaxel 6Nivolumab 5Erlotinib Hydrochloride 5130-nm albumin-bound paclitaxel 5capmatinib 3brigatinib 3anlotinib 3Gefitinib 3Drug Therapy 3vosaroxin 2volociximab 2sintilimab 2pralsetinib 2ensartinib 2atezolizumab 2aflibercept 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × motexafin gadolinium × Thoracic × Clear all
NCT00365183 2013-10-31

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Pharmacyclics LLC.

Phase 2 Terminated
74 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡